190 related articles for article (PubMed ID: 27238400)
1. Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies.
Ni M; Hoffmann JM; Schmitt M; Schmitt A
Expert Opin Biol Ther; 2016 Sep; 16(9):1113-23. PubMed ID: 27238400
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
8. Advances in dendritic cell-based vaccine of cancer.
Zhang X; Gordon JR; Xiang J
Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
Burdin N; Moingeon P
Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
[TBL] [Abstract][Full Text] [Related]
10. Next-generation dendritic cell-based vaccines for leukemia patients.
Hoffmann JM; Schmitt M; Ni M; Schmitt A
Immunotherapy; 2017 Jan; 9(2):173-181. PubMed ID: 28128712
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
12. mRNA Cancer Vaccines.
Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
[TBL] [Abstract][Full Text] [Related]
13. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
14. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
15. Hematologic neoplasms: Dendritic cells vaccines in motion.
Galati D; Zanotta S
Clin Immunol; 2017 Oct; 183():181-190. PubMed ID: 28870867
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
17. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
